Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: A review of the literature

Atherosclerosis

Volumn 242, Issue 2, 2015, Pages 647-656

  Ito, Matthew K ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b SANOFI   (France)

Author keywords

Fibrates; Hypertriglyceridemia; Long chain omega 3 fatty acids; Niacin; Statins; Triglycerides

Indexed keywords

CREATININE; FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIVER ENZYME; LONG CHAIN FATTY ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

BLURRED VISION; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHOLELITHIASIS; CLINICAL EVALUATION; CUTANEOUS VASODILATATION; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; INSULIN RESISTANCE; LIPID ANALYSIS; MEDLINE; META ANALYSIS (TOPIC); NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; SKIN BLOOD VESSEL DISORDER; TOXIC MYOPATHY; TREATMENT OUTCOME; BLOOD; CARDIOVASCULAR DISEASES; METABOLISM;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FATTY ACIDS, OMEGA-3; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; LIPIDS; NIACIN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84941747401     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.06.012     Document Type: Review

References (102)

1. Maki K.C., Bays H.E., Dicklin M.R. Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence. J. Clin. Lipidol. 2012, 6:413-426.
2. Kotseva K., Wood D., De Backer G., et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur. J. Cardiovasc. Prev. Rehabil. 2009, 16:121-137.
3. Miller M., Stone N.J., Ballantyne C., et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123:2292-2333.
4. Catapano A.L., Reiner Z., De Backer G., et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217:3-46.
5. Chapman M.J., Ginsberg H.N., Amarenco P., et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 2011, 32:1345-1361.
6. Berglund L., Brunzell J.D., Goldberg A.C., et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2012, 97:2969-2989.
7. Jellinger P.S., Smith D.A., Mehta A.E., et al. American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr. Pract. 2012, 18(Suppl. 1):1-78.
8. Hegele R.A., Ginsberg H.N., Chapman M.J., et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014, 2:655-666.
9. Jacobson T.A., Ito M.K., Maki K.C., et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1-executive summary. J. Clin. Lipidol. 2014, 8:473-488.
10. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
11. Nordestgaard B.G., Benn M., Schnohr P., et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308.
12. Varbo A., Benn M., Tybjaerg-Hansen A., et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J. Am. Coll. Cardiol. 2013, 61:427-436.
13. Brunzell J.D., Schrott H.G. The interaction of familial and secondary causes of hypertriglyceridemia: role in pancreatitis. Trans. Assoc. Am. Physicians 1973, 86:245-254.
14. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18:499-502.
15. Hermans M.P., Ahn S.A., Rousseau M.F. Novel unbiased equations to calculate triglyceride-rich lipoprotein cholesterol from routine non-fasting lipids. Cardiovasc. Diabetol. 2014, 13:56.
16. Miller M., Cannon C.P., Murphy S.A., et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol. 2008, 51:724-730.
17. Nordestgaard B.G., Wootton R., Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler. Thromb. Vasc. Biol. 1995, 15:534-542.
18. Alaupovic P., Mack W.J., Knight-Gibson C., et al. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler. Thromb. Vasc. Biol. 1997, 17:715-722.
19. Zheng X.Y., Liu L. Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase. J. Lipid Res. 2007, 48:1673-1680.
20. Wang L., Gill R., Pedersen T.L., et al. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J. Lipid Res. 2009, 50:204-213.
21. Ting H.J., Stice J.P., Schaff U.Y., et al. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha. Circ. Res. 2007, 100:381-390.
22. Ginsberg H.N. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002, 106:2137-2142.
23. Preiss D., Tikkanen M.J., Welsh P., et al. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA 2012, 308:804-811.
24. Edwards J.E., Moore R.A. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam. Pract. 2003, 4:18.
25. AstraZeneca Crestor US Prescribing Information 2014, Available from:. http://www1.astrazeneca-us.com/pi/crestor.pdf.
26. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 1987, 317:1237-1245.
27. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 1999, 341:410-418.
28. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102:21-27.
29. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
30. Birjmohun R.S., Hutten B.A., Kastelein J.J., et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. 2005, 45:185-197.
31. Robinson J.G., Wang S., Smith B.J., et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J. Am. Coll. Cardiol. 2009, 53:316-322.
32. Davidson M.H., Bays H.E., Stein E., et al. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin. Cardiol. 2006, 29:268-273.
33. Farnier M. Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. Vasc. Health Risk Manag. 2008, 4:991-1000.
34. Rizzo M., Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM 2006, 99:1-14.
35. Rajman I., Eacho P.I., Chowienczyk P.J., et al. LDL particle size: an important drug target?. Br. J. Clin. Pharmacol. 1999, 48:125-133.
36. McCullough P.A., Ahmed A.B., Zughaib M.T., et al. Treatment of hypertriglyceridemia with fibric acid derivatives: impact on lipid subfractions and translation into a reduction in cardiovascular events. Rev. Cardiovasc. Med. 2011, 12:173-185.
37. Staels B., Dallongeville J., Auwerx J., et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998, 98:2088-2093.
38. McCullough P.A., Di Loreto M.J. Fibrates and cardiorenal outcomes. J. Am. Coll. Cardiol. 2012, 60:2072-2073.
39. Nikolic D., Katsiki N., Montalto G., et al. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients 2013, 5:928-948.
40. Hoogeveen R.C., Gaubatz J.W., Sun W., et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler. Thromb. Vasc. Biol. 2014, 34:1069-1077.
41. Otvos J.D., Collins D., Freedman D.S., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006, 113:1556-1563.
42. Jun M., Foote C., Lv J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375:1875-1884.
43. Manninen V., Tenkanen L., Koskinen P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992, 85:37-45.
44. Scott R., O'Brien R., Fulcher G., et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009, 32:493-498.
45. Lee M., Saver J.L., Towfighi A., et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 2011, 217:492-498.
46. Ginsberg H.N., Elam M.B., Lovato L.C., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 2010, 362:1563-1574.
47. Guyton J.R., Goldberg A.C., Kreisberg R.A., et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am. J. Cardiol. 1998, 82:737-743.
48. Elam M.B., Hunninghake D.B., Davis K.B., et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000, 284:1263-1270.
49. Nordestgaard B.G., Chapman M.J., Ray K., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 2010, 31:2844-2853.
50. Morgan J.M., Capuzzi D.M., Baksh R.I., et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am. J. Cardiol. 2003, 91:1432-1436.
51. Bays H., Giezek H., McKenney J.M., et al. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metab. Syndr. Relat. Disord. 2012, 10:260-266.
52. Akinkuolie A.O., Paynter N.P., Padmanabhan L., et al. High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease. Circ. Cardiovasc. Qual. Outcomes 2014, 7:55-63.
53. Bruckert E., Labreuche J., Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010, 210:353-361.
54. Lavigne P.M., Karas R.H. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J. Am. Coll. Cardiol. 2013, 61:440-446.
55. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 1986, 8:1245-1255.
56. The coronary drug project. Design, methods, and baseline results. Circulation 1973, 47:I1-I50. The Coronary Drug Project Research Group.
57. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 2013, 34:1279-1291.
58. Landray M.J., Haynes R., Hopewell J.C., et al. Effects of extended-release niacin with laropiprant in high-risk patients. N. Engl. J. Med. 2014, 371:203-212.
59. Boden W.E., Probstfield J.L., Anderson T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 2011, 365:2255-2267.
60. Harris W.S. n-3 fatty acids and serum lipoproteins: human studies. Am. J. Clin. Nutr. 1997, 65:1645S-1654S.
61. Kastelein J.J., Maki K.C., Susekov A., et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J. Clin. Lipidol. 2014, 8:94-106.
62. Bays H.E., Ballantyne C.M., Kastelein J.J., et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label extension [MARINE] trial). Am. J. Cardiol. 2011, 108:682-690.
63. Weintraub H.S. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. Postgrad. Med. 2014, 126:7-18.
64. Balk E.M., Lichtenstein A.H., Chung M., et al. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006, 189:19-30.
65. Griffin B.A. The effect of n-3 fatty acids on low density lipoprotein subfractions. Lipids 2001, 36(Suppl. l):S91-S97.
66. Lee M.W., Park J.K., Hong J.W., et al. Beneficial effects of Omega-3 fatty acids on low density lipoprotein particle size in patients with type 2 diabetes already under statin therapy. Diabetes Metab. J. 2013, 37:207-211.
67. Annuzzi G., Rivellese A.A., Wang H., et al. Lipoprotein subfractions and dietary intake of n-3 fatty acid: the Genetics of Coronary Artery Disease in Alaska Natives study. Am. J. Clin. Nutr. 2012, 95:1315-1322.
68. Amarin Corporation plc Vascepa Prescibing Information 2014, Available from:. http://www.vascepa.com/full-prescribing-information.pdf.
69. GlaxoSmithKline plc Lovaza Prescribing Information 2014, Available from:. https://www.gsksource.com/gskprm/htdocs/documents/LOVAZA-PI-PIL.PDF.
70. AstraZeneca Epanova Prescribing Information 2014, Available from:. http://www1.astrazeneca-us.com/pi/epanova.pdf.
71. ® in a pharmacokinetic single-dose evaluation) study. J. Clin. Lipidol. 2012, 6:573-584.
72. Weitz D., Weintraub H., Fisher E., et al. Fish oil for the treatment of cardiovascular disease. Cardiol. Rev. 2010, 18:258-263.
73. Albert B.B., Derraik J.G., Cameron-Smith D., et al. Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. Sci. Rep. 2015, 5:7928.
74. Zargar A., Ito M.K. Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal Supplement Database. Metab. Syndr. Relat. Disord. 2011, 9:255-271.
75. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999, 354:447-455.
76. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
77. Kromhout D., Giltay E.J., Geleijnse J.M. n-3 fatty acids and cardiovascular events after myocardial infarction. N. Engl. J. Med. 2010, 363:2015-2026.
78. Rauch B., Schiele R., Schneider S., et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010, 122:2152-2159.
79. Roncaglioni M.C., Tombesi M., Avanzini F., et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N. Engl. J. Med. 2013, 368:1800-1808.
80. Kotwal S., Jun M., Sullivan D., et al. Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ. Cardiovasc. Qual. Outcomes 2012, 5:808-818.
81. Rizos E.C., Ntzani E.E., Bika E., et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012, 308:1024-1033.
82. Clinicaltrials.gov A Study of AMR101 to Evaluate its Ability to Reduce Cardiovascular Events in High Risk Patients with Hypertriglyceridemia and on Statin. The Primary Objective Is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. (REDUCE-IT) 2014, Available from:. https://clinicaltrials.gov/ct2/show/NCT01492361.
83. Clinicaltrials.gov Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in High CV Risk PatienTs with Hypertriglyceridemia (STRENGTH) 2015, Available from:. https://clinicaltrials.gov/ct2/show/NCT02104817.
84. Davidson M.H., Armani A., McKenney J.M., et al. Safety considerations with fibrate therapy. Am. J. Cardiol. 2007, 99:3C-18C.
85. Gaist D., Rodriguez L.A., Huerta C., et al. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001, 12:565-569.
86. Graham D.J., Staffa J.A., Shatin D., et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004, 292:2585-2590.
87. Chang J.T., Staffa J.A., Parks M., et al. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol. Drug Saf. 2004, 13:417-426.
88. Holoshitz N., Alsheikh-Ali A.A., Karas R.H. Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. Am. J. Cardiol. 2008, 101:95-97.
89. Kyrklund C., Backman J.T., Neuvonen M., et al. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin. Pharmacol. Ther. 2003, 73:538-544.
90. Guyton J.R., Bays H.E. Safety considerations with niacin therapy. Am. J. Cardiol. 2007, 99:22C-31C.
91. Sazonov V., Maccubbin D., Sisk C.M., et al. Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. Int. J. Clin. Pract. 2013, 67:297-302.
92. Davidson M.H., Stein E.A., Bays H.E., et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin. Ther. 2007, 29:1354-1367.
93. Ballantyne C.M., Bays H.E., Kastelein J.J., et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am. J. Cardiol. 2012, 110:984-992.
94. Wang C., Harris W.S., Chung M., et al. n-3 fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am. J. Clin. Nutr. 2006, 84:5-17.
95. Filion K.B., El Khoury F., Bielinski M., et al. Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc. Disord. 2010, 10:24.
96. Harris W.S., Ginsberg H.N., Arunakul N., et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J. Cardiovasc. Risk 1997, 4:385-391.
97. McKenney J.M., Swearingen D., Di Spirito M., et al. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. J. Clin. Pharmacol. 2006, 46:785-791.
98. Di Spirito M., Morelli G., Doyle R.T., et al. Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults. Expert Opin. Pharmacother. 2008, 9:2939-2945.
99. Kostapanos M.S., Milionis H.J., Elisaf M.S. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am. J. Cardiovasc. Drugs 2010, 10:11-28.
100. Wei M.Y., Jacobson T.A. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr. Atheroscler. Rep. 2011, 13:474-483.
101. Jacobson T.A., Glickstein S.B., Rowe J.D., et al. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J. Clin. Lipidol. 2012, 6:5-18.
102. Stone N.J., Robinson J.G., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J. Am. Coll. Cardiol. 2014, 63:2889-2934.